N
NeuroVision
Detecting neurodegenerative diseases
About NeuroVision
NeuroVision is a pioneering company in the healthcare sector, specializing in the development of proprietary blood tests and advanced retinal imaging software. These innovations are designed to track key neurological biomarkers and ocular features, providing critical feedback to clinicians and motivation to patients. The company's blood tests aim to delay the onset of cognitive decline by enabling lifestyle risk reduction, while its retinal imaging software helps doctors identify and manage retinal diseases more effectively. NeuroVision collaborates closely with pharmaceutical companies to explore complementary and companion biomarker opportunities. The company primarily serves healthcare providers, clinicians, and pharmaceutical firms, operating in the medical diagnostics and biotechnology markets. NeuroVision's business model revolves around the development and commercialization of its diagnostic tools, generating revenue through partnerships, licensing agreements, and direct sales of its products.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2010
- Headquarters
- Sacramento, United States
- Employees
- 21
- Open positions
- None listed
- Dealroom signal
- 82.5/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Drug Development, Neurology, Alzheimers Disease, Core AI
- Technology
- Artificial Intelligence, Big Data, Deep Tech, Computer Vision
- Business model
- SaaS
- Client focus
- b2b
- Investment activity
- 1 company, latest May 2026
- Capital deployed
- —
- Preferred round
- ACQUISITION
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VC✓Equity / VC | Aug 2021 | $0 | — | Alzheimer's Drug Discovery Foundation | — |
| GRANTOther financing | Feb 2021 | — | — | Alzheimer's Drug Discovery Foundation | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for NeuroVision is 3K monthly website visits, up 130.8% over the last three months. NeuroVision's team grew 23.5% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Alzheimer's Drug Discovery Foundation
Series A1 investor entered at this stage
Wildcat Capital Management
Other known investors2 additional known investors
Cedars-Sinai
Omega Funds
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about NeuroVision on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See NeuroVision’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.